Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in human plasma

Biomedical Chromatography

Volumn 27, Issue 1, 2013, Pages 34-38

  Wang, Haidong ^a,b   Deng, Pan ^b   Chen, Xiaoyan ^b   Guo, Lixia ^b   Zhong, Dafang ^a,b  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Febuxostat; Liquid chromatography with tandem mass spectrometry detection; Pharmacokinetic

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS; PLASMA (HUMAN); PLASMA DIAGNOSTICS; PLASMA STABILITY; POSITIVE IONS;

ANALYTES; ANALYTICAL METHOD; FEBUXOSTAT; HUMAN PLASMAS; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY COUPLED TO TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY (LCMS/MS); LIQUID CHROMATOGRAPHY WITH TANDEM MASS SPECTROMETRY DETECTION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY;

ACETONITRILE;

ACETONITRILE; AMMONIUM ACETATE; FEBUXOSTAT; FORMIC ACID;

ACCURACY; ARTICLE; ATMOSPHERIC PRESSURE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PH; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

EID: 84871107959     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2744     Document Type: Article

References (11)

1. De Bont JM and Pieters R. Management of hyperuricemia with rasburicase review. Nucleosides, Nucleotides & Nucleic Acids 2004; 23: 1431-1440.
2. Ernst ME and Fravel MA. Febuxostst: a selective xanthine oxidase/xanthine dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clinical Therapeutics 2009; 31: 2503-2518.
3. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N and Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. The Journal of Clinical Pharmacology 2006; 46(1): 88-102.
4. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N and Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clinical Pharmacokinetics 2006; 45: 821-841.
5. Khosravan R, Wu JT, Joseph-Ridge N and Vernillet L. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. The Journal of Clinical Pharmacology 2006; 46: 855-866.
6. Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N and Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. British Journal of Clinical Pharmacology 2008; 65: 355-363.
7. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3630.
8. Schumacher HR. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hypreuricaemia in patients with gout. Expert Opinion on Investigational Drugs 2005; 14: 893-903.
9. Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S and Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sciences 2005; 76: 1835-1347.
10. USFDA. 2008. Guidance for Industry on Safety Testing of Drug Metabolites. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance Regulatory Information/Guidances/ucm079266.pdf (accessed 19 June, 2011).
11. Yu KH. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. Recent Patent on Inflammation and Allergy Drug Discovery 2007; 1: 169-175.